Skip to Main Content

New York hedge fund Kerrisdale Capital is betting on the failure of Sage Therapeutics’ (SAGE) drug for severe epilepsy with results from a phase 3 clinical trial expected next month.

“We are short Sage going into the trial because nothing has changed from our original thesis,” Kerrisdale founder and Chief Investment Officer Sahm Adrangi told me Friday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED